Breast Cancer | Disease Landscape and Forecast | G7 | 2020
The breast cancer market is rapidly evolving and presents new commercial opportunities for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio / Verzenios) are creating new dynamics in the metastatic HR-positive / HER2-negative treatment practice. In HER2-positive breast cancer, HER2-targeting drugs in development are forecast to enter the market, while sales of current HER2-targeting agents will be impacted as a result of competition, label expansions, biosimilar entries, and new trials leading to changes in treatment guidelines. Furthermore, the approval of PARP inhibitors (AstraZeneca / Merck & Co.’s Lynparza and Pfizer’s Talzenna), PD-1-targeting agents (Roche / Genentech / Chugai’s Tecentriq), PI3K inhibitors (Novartis’s Piqray), HER2-targeting agents (Daiichi Sankyo / AstraZeneca’s Enhertu, Seagen’s Tukysa, and MacroGenics’ Margenza), TROP2-targeting antibody-drug conjugates (Immunomedics’ Trodelvy), and the anticipated entry of other agents from these drug classes will diversify treatment options, especially for triple-negative breast cancer.
What is the size of the drug-treatable breast cancer population, and how will drug-treatment rates change over time?
What is the expected market impact of recent drug approvals, such as Tecentriq, Piqray, Enhertu, Tukysa, and Trodelvy on the various subpopulations of breast cancer?
What are the most promising agents in the pipeline, and how will they shape the future of the breast cancer market?
What are the drivers and constraints in the breast cancer market, and how will the market evolve over the forecast period?
Geographies: United States, EU5, Japan
Primary Research: 19 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other DRG research
Epidemiology: Incidence of breast cancer by country, segmented by HR and HER2 status, staging, and line of therapy
Forecast: 10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2029, segmented by brands / biosimilars / generics and market-relevant drug-treatable populations
Emerging Therapies: Phase III/PR: 15 drugs; coverage of select Phase I and II products
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.